GSK2850163 hydrochloride

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

GSK2850163 hydrochloride 

GSK2850163 hydrochloride 是一个新型的肌醇需要酶-1α (IRE1α) 抑制剂,它可抑制 IRE1α 的激酶活性和 RNA 酶活性,其 IC50 值分别为 20 和 200 nM。

GSK2850163 hydrochloride

GSK2850163 hydrochloride Chemical Structure

CAS No. : 2319838-09-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

GSK2850163 hydrochloride 的其他形式现货产品:

GSK2850163

生物活性

GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively.

IC50 & Target

IC50: 20 nM (IRE1α kinase activity), 200 nM (IRE1α RNase activity)[1]

体外研究
(In Vitro)

GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively. The increased autophosphorylation of IRE1α can be reduced in a dose-dependent manner by GSK2850163 hydrochloride. Increasing concentrations of GSK2850163 hydrochloride are capable of reducing the increased XBP 1 transcriptional activity. Two additional kinases are weakly inhibited by GSK2850163 hydrochloride: Ron (IC50=4.4 μM) and FGFR1 V561M (IC50=17 μM)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

482.87

Formula

C24H30Cl3N3O

CAS 号

2319838-09-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Nestor O. Concha, et al. Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity. Molecular Pharmacology December 2015, 88 (6) 1011-1023.

Kinase Assay
[1]

In the ADP-Glo assay, GSK2850163 hydrochloride’s potency toward pIRE1α kinase activity is measured as its inhibition of an intrinsic, slowing ATP hydrolysis activity. One hundred nanoliters of dimethylsulfoxide solution of GSK2850163 hydrochloride at various concentrations is added into a 384-well plate. The reaction is carried out with 5 nM pIRE1α and 60 mM ATP in 10 mL of 50 mM Hepes buffer, pH 7.5, containing 30 mM NaCl, 10 mM MgCl2, 1 mM DTT, 0.02% Chaps, and 0.01 mg/mL bovine serum albumin. The reaction is stopped after 2 hours by adding 5 mL of ADP-Glo reagent I, which also depletes the remaining ATP. Following 1-hour incubation, 5 mL of ADP-Glo reagent II is added into the reaction, which converts the ADP product into ATP to serve as the substrate for the coupled luciferin/luciferase reaction. After 30 minutes, the plate is read on a microplate imager[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

PANC-1 cells are seeded into six-well plates at a density of 5.0×103 cells/well in RPMI 1640 media containing 10% FBS. Cells are cotransfected with a pGL3-5x unfolded protein response element (UPRE)-luciferase reporter containing five repetitions of the XBP-1 DNA binding site and pRL-SV40 using the FuGENE6 transfection reagent. Forty-eight hours later, cells are treated with 2.5 mg/mL tunicamycin for 1 hour, followed by GSK2850163 hydrochloride treatment for 16 hours. Luciferase expression is measured using Dual-Glo Luciferase Assay kit and normalized to Renilla expression levels[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Nestor O. Concha, et al. Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity. Molecular Pharmacology December 2015, 88 (6) 1011-1023.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

发表回复